Kadir Kadhiresan
Vice President, Venture Investments @ Johnson & Johnson Development Corporation
Cambridge, United States
Kadir Kadhiresan is a Series D investor at Johnson & Johnson Development Corporation in Cambridge focused on Health Care and Medical Device. V. Kadir Kadhiresan, PhD, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment and business development experience.Based in Boston, Kadir works closely with Johnson & Johnson leadership to identifybusiness needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP).Before joining JJDC, Kadir was head of Business Development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Kadir Kadhiresan invests in
Stages Kadir Kadhiresan invests in
Countries Kadir Kadhiresan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (57%)
- Medical Device 4 (57%)
- Medical 3 (43%)
- Neuroscience 1 (14%)
- Biotechnology 1 (14%)
Stage
- Series D 2 (29%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
- Convertible Note 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M / Series D / Aug 15, 2024 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $85M / Convertible Note / Dec 13, 2022 | ||
| Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HyalexOrthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency. | $17M / Series A / Mar 28, 2019 | ||
| Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HyalexOrthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency. | $16M / Series A / May 31, 2017 | ||
| Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California.According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population.Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable.The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot.By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators. | Series D / Jun 15, 2011 | ||
| Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California.According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population.Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable.The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot.By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators. | Series C / Nov 09, 2009 | ||
| NeoTract, Inc. develops surgical devices for urological and gynecological disorders. | $28.1M / Series B / Sep 15, 2009 |
Co-Investors
Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms,JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.
Johnson & Johnson Development Corporation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Asish Xavier
Vice President, Venture Investments
|
|||
|
Kadir Kadhiresan
Vice President, Venture Investments
|
|||
James J. Bergin
Vice President Law
|
|||
Jeanne Bolger
Vice President Venture Investing
|
|||
Marian Nakada
Vice President, Venture Investments
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kadir Kadhiresan invest in?
Kadir Kadhiresan invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kadir Kadhiresan?
Public channels for Kadir Kadhiresan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kadir Kadhiresan last invest?
The most recent investment recorded for Kadir Kadhiresan closed in Aug 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
